Dasatinib 化学構造
分子量: 488.01

高品質保証

文献中の引用(61)

カスタマーフィードバック(10)

Quality Control & MSDS

製品説明

  • Compare Src Inhibitors
    Src製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

製品説明 Dasatinib は、野生型ablとSrcのためのSrc/abl阻害剤で、IC50 がそれぞれ 0.6 nM と 0.8 nMです。
ターゲット Abl Src c-Kit (WT)/c-Kit (D816V)
IC50

0.6 nM

0.8 nM [1]

79 nM/37 nM [2]
In vitro試験 Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
M07ep210 M375XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXy3NkBp MlnxSG1UVw>? NYSxN3dRUUN3ME2wMlAxODB5IN88US=> NIPLfFAyPzl3NkC4NC=>
K562 NV:xdGQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4OyWlczKGh? M{DCO2ROW09? M{DuNGlEPTB;MD6wNFEh|ryP MVSxO|k2PjB6MB?=
M07e MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXYO|IhcA>? NFHmV2xFVVOR M2fpSWlEPTB;MD6wNFEzKM7:TR?= NVv6OodZOTd7NU[wPFA>
ALL3 Ml;tR5l1d3SxeHnjJGF{e2G7 NXvlVZEzOC5zzszN NFPPdVY4OiCq MWfEUXNQ NUjlSpNiUUN3ME2wMlAxODRizszN NVrVc|dIOTl6OEm1OFA>
CML NXzOdVhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFH5N4YzOCCvaX6= NGXTU4FFVVOR NGnUUIlKSzVyPUCuNFAyKM7:TR?= MX6xPVIyQTBzNh?=
BA/F3 M1zPdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlGyO|IhcA>? MnvnSG1UVw>? M{DrSmlEPTB;Nj61PFkh|ryP NFHSOVgzOzB6OE[0OC=>
BA/F3 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXWO|IhcA>? MWfEUXNQ NHvmZY1KdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW|c3nu[{BD[3JvQXLsJG0{PTGWIH31eIFvfCC5aYToJGlEPTBib3[gNE4xODB6M988US=> NWH1cIRFOjNyOEi2OFQ>
BA/F3 NE\kTotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TaV|czKGh? M1TVPGROW09? M4DibWlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO|aX7nJJdqdGRidInw[UBD[3JvQXLsJJdqfGhiSVO1NEBw\iByLkCwOFXPxE1? NV7sOWtPOjNyOEi2OFQ>
BA/F3 MlvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHuyVpk4OiCq M37GeWROW09? MW\JcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDCZ5IuSWKuIGSzNVVKKG23dHHueEB4cXSqIFnDOVAhd2ZiMT63NVTPxE1? MV6yN|A5QDZ2NB?=
BA/F3 NGLzbWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;TflczKGh? M1XHcmROW09? MkjWTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTjR6NmOgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNFnPxE1? M3z2T|I{OzBzN{Cz
BA/F3 MkLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfYcFREPzJiaB?= Mme5SG1UVw>? Ml7HTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTTJ3NVugcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwN|LPxE1? Mlq0NlM{ODF5MEO=
BA/F3 M2rrSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\0OII4OiCq MmrFSG1UVw>? M2\Wb2lv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEd{NUDFJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFUy|ryP MXqyN|MxOTdyMx?=
BA/F3 M376Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUK3NkBp NEnzd5hFVVOR NX;EcWNvUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiUUK1NmghdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxQM7:TR?= NW\kZnBnOjN|MEG3NFM>
BA/F3 MmGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILkR5Y4OiCq MmLkSG1UVw>? NHnaZ3NKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCHM{W5WkBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFAyO87:TR?= NX;4b283OjN|MEG3NFM>
BA/F3 M1n5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYO3NkBp NFLlTIVFVVOR NYrKe|IzUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIIfpcIQhfHmyZTDCR3IuSUKOIHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNVnPxE1? NYHIbW52OjN|MEG3NFM>
BA/F3 MmDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV[3NkBp NHfHeXFFVVOR MlLLTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhYTJ3M1igcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNlPPxE1? M4nQVFI{OzBzN{Cz
BA/F3 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULwWFJkPzJiaB?= M1:yNmROW09? NEjKbohKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCWM{G1TUBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIEOuOu69VQ>? NVzoWYlyOjN|MEG3NFM>
BA/F3 Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7WRpo4OiCq NIfzVlhFVVOR M{XlUGlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKEmwaHnibZRqd25id3n0bEBKSzVyIH;mJFIvPc7:TR?= Ml7XNlM{ODF5MEO=
T cell MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\sO|IhcA>? M4jYSGROW09? Mn7FTY5pcWKrdIOgZY51cSCFREOtJIFv\CCjboTpJGNFOjhvaX7keYNm\CCWIHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5yMEROwG0> NUHBd45UOTdzNUS1NVI>
WiDr MljIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfBdZNZPzJiaB?= M2PSTWROW09? NFXTNYRKSzVyPUCuNFUzKM7:TR?= M3X1flE2PjF3NUGy
PC3 NHKyO|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTvPFA4OiCq M1;6OmROW09? NVGxd5htUUN3ME2wMlAxQTRizszN MYexOVYyPTVzMh?=
MDA-MB-231 M33mdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWi3NkBp NYW0XHYxTE2VTx?= NED2TGZKSzVyPUCuNFEzKM7:TR?= M1vreFE2PjF3NUGy
Hs578T M2KxUGN6fG:2b4jpZ{BCe3OjeR?= MnXOO|IhcA>? M2fV[GROW09? MlLrS2k2OD1yLkCzJO69VQ>? NF:xPXczPDBzNUOyOy=>
HMEC M4D5W2N6fG:2b4jpZ{BCe3OjeR?= MlPBO|IhcA>? MUHEUXNQ MX\HTVUxRTFwODFOwG0> M1jSblI1ODF3M{K3
DU145 MlfKR5l1d3SxeHnjJGF{e2G7 M3;pXlczKGh? MWnEUXNQ NGntPVJIUTVyPUCuNVYh|ryP M37qeVI1ODF3M{K3
U251 MYHDfZRwfG:6aXOgRZN{[Xl? M1nJc|czKGh? MkPYSG1UVw>? MkK2S2k2OD1{LkixJO69VQ>? MWqyOFAyPTN{Nx?=
NCI60 MmLGR5l1d3SxeHnjJGF{e2G7 NF7HXYs4OiCq NWD0SI15TE2VTx?= NWPwVmgyT0l3ME21Mlch|ryP MnPhNlQxOTV|Mke=
MALME-3M NGX5boNEgXSxdH;4bYMhSXO|YYm= MXm3NkBp NFy4SohFVVOR NVfONFloT0l3ME22MlYyKM7:TR?= M13FN|I1ODF3M{K3
KM12 NGLEW5VEgXSxdH;4bYMhSXO|YYm= NULmOJBnPzJiaB?= MXfEUXNQ MnLFS2k2OD15LkS0JO69VQ>? NFPaUZIzPDBzNUOyOy=>
SW620 NG\nUIJEgXSxdH;4bYMhSXO|YYm= M{\5eFczKGh? NGjmeGxFVVOR MYLHTVUxRThwNEOg{txO MYqyOFAyPTN{Nx?=
RXF 393NL NYfSPHdFS3m2b4TvfIlkKEG|c3H5 MUi0JIRigXN? NHnYbZFFVVOR NFO3b|NKSzVyPUCuNFIyPyEQvF2= NXXrXIV4OjN{NUOwO|Q>
LXFA 983L NXXIfWh6S3m2b4TvfIlkKEG|c3H5 NWKw[FZPPCCmYYnz MmTISG1UVw>? NEXyPXdKSzVyPUCuNFU3PSEQvF2= M{T5S|I{OjV|MEe0
PRXF DU145 NULlc|I1S3m2b4TvfIlkKEG|c3H5 NXfq[WxmPCCmYYnz M1PzU2ROW09? MknnTWM2OD1yLkC2NlMh|ryP MWeyN|I2OzB5NB?=
PAXF 1657L NVnTdGJJS3m2b4TvfIlkKEG|c3H5 NGO3R2U1KGSjeYO= NVvTd21vTE2VTx?= NHTVNWhKSzVyPUCuNVIyKM7:TR?= MVeyN|I2OzB5NB?=
CXF 1103L MXjDfZRwfG:6aXOgRZN{[Xl? MojUOEBl[Xm| MVXEUXNQ M{DxbmlEPTB;ND6zOkDPxE1? NF;hd4gzOzJ3M{C3OC=>
GXF251L NUnLT2ExS3m2b4TvfIlkKEG|c3H5 MWG0JIRigXN? NXeyTo5CTE2VTx?= MV\JR|UxRTJwMkWg{txO NGjmd2kzOzJ3M{C3OC=>
NCI-H23 MojNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XwPFczKGh? Mnv0SG1UVw>? NITsW29KSzVyPUKuNlch|ryP MVSyN|UzOTB{MB?=
HCT116 NGLPc3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUW3NkBp MoDhSG1UVw>? NWn6So1MUUN3ME2yMlMh|ryP NV7NWYgzOjN3MkGwNlA>
MCF7 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXK3NkBp M2rvTWROW09? M2fBTGlEPTB;Mj61O{DPxE1? M4CxPFI{PTJzMEKw
NCI-H460 NIG5VnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfoNFllPzJiaB?= NV3jSII6TE2VTx?= Mn7uTWM2OD16Lkm5JO69VQ>? NIflO|YzOzV{MUCyNC=>
DLD1 M1qx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjwO|IhcA>? NFTGZ3RFVVOR NVTEZ|JkUUN3ME20MlYh|ryP MnTjNlM2Pjd7NkC=
NCI-H661 M1nZbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH:1[HU4OiCq NX3GZnpMTE2VTx?= NIHkcItKSzVyPUeuPEDPxE1? M3LtXFI{PTZ5OU[w
A549 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPLO|IhcA>? MXPEUXNQ MXvJR|UxRThwMjFOwG0> M{fWeFI{PTZ5OU[w
U937 NFLkcY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXu3NkBp NEPsTFdFVVOR NWPMNXpLUUN3ME2xNk4zKM7:TR?= MUKyN|U3Pzl4MB?=
HEK293 NVPZXWFPTnWwY4Tpc44hSXO|YYm= Ml3XNVDDqM7:TR?= NFTsPJVFVVOR MkH2TY5lfWOnczDibY5lcW6pIHHm[olvcXS7IITvJIh2dWGwIH\1cIwudGWwZ4ToJGhqey22YXfn[YQhVXm2MTDrbY5ie2ViZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyC5aYToJGlEPTBib3[gNE4xPjQQvF2= Mm\lNlI4PzB4MUC=
HUVEC MofyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PzV|AvOTYEoN88US=> MYq3NkBp NIOz[FJFVVOR NGrFRW1KdmS3Y3XzJIFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHnuJGhWXkWFIHPvMYN2dHS3cnXkJJdqfGhidnHzZ5Vt[XJic33vc5RpKG23c3Ps[UBk\WyuczDhd5Nme3OnZDDhd{BKdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIF1KDBwMUWgeW0> MX:yNlg2Ozl7Mx?=
HUVEC MXHGeY5kfGmxbjDBd5NigQ>? NGDneIEyPcLizszN MkXpO|IhcA>? M4DjbWROW09? NVfkN|RsUW6mdXPld{BidnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDjc{1kfWy2dYLl[EB4cXSqII\hd4N2dGG{IIPtc491cCCvdYPjcIUh[2WubIOgZZN{\XO|ZXSgZZMhUW6qaXLpeIlwdiCxZjDu[ZR4d3KtIH\vdo1ifGmxbjDheEAyNjhidH:gNVUhfU1? NV:4W3lCOjJ6NUO5PVM>
Plasmodium falciparum NEn4[lNHfW6ldHnvckBCe3OjeR?= MUWxNOKh|ryP MlfnNVUhdWmw MkjDSG1UVw>? NHvoVlhKdmirYnn0d{BRdGG|bX;kbZVuKG[jbHPpdIFzfW1icILvcIln\XKjdHnvckBjgSCrbnjpZol1cW6pIITo[UBHfW6ldHnvckBw\iCSZlPEVGsyKHC{b4TlbY4hf2m2aDDJR|UxKG:oIEGuNVfPxE1? NHy3[|AzPDV3MEOzNC=>
PC3 MmP3SpVv[3Srb36gRZN{[Xl? NUjEXVhIOC5zIN88US=> MXG1JIg> NFXQU25FVVOR MnXPTY5pcWKrdIOgbJVu[W5iUFOzJINmdGxiYXTo[ZNqd25iYYSgNVAxKG6P M4TSUVE6PDZ{OUe1
DU145 NGGzd|RHfW6ldHnvckBCe3OjeR?= NXG3WlBDOC5zIN88US=> MVi1JIg> MXLEUXNQ NInNNo9KdmirYnn0d{BpfW2jbjDEWVE1PSClZXzsJIFlcGW|aX;uJIF1KDFyMDDuUS=> M1[2ZlE6PDZ{OUe1
PC3 NInu[JhMcW6jc3WgRZN{[Xl? NXS2TosyOC5zIN88US=> NUH2e29TPSCq Ml\uSG1UVw>? MULJcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgV5JkKFl2MU[gcIV3\WxiYYSgNVAxKG6P MVixPVQ3Ojl5NR?=
DU145 NH;oNWFMcW6jc3WgRZN{[Xl? MoDFNE4yKM7:TR?= MlnhOUBp M2fjUGROW09? NUTVN2RNUW6qaXLpeJMh[1O{YzDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gdIhwe3Cqb4L5cIF1\WRiU4LjJHk1OTZibHX2[Ywh[XRiMUCwJI5O MWWxPVQ3Ojl5NR?=
PC3 NV3BdIhsU2mwYYPlJGF{e2G7 M4DpclAvOSEQvF2= MkDCOUBp NEHCOXVFVVOR M3m3OGlvcGmkaYTzJINUemNiaX6gbJVu[W5iUFOzJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBHSUtiWUW3Ok9[PTd5IHzleoVtKGG2IEGwNEBvVQ>? NGi5SY4yQTR4Mkm3OS=>
DU145 NXzyXZdHU2mwYYPlJGF{e2G7 M{XISFAvOSEQvF2= Mn3MOUBp MlzsSG1UVw>? M130OWlvcGmkaYTzJINUemNiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKE[DSzDZOVc3N1l3N{egcIV3\WxiYYSgNVAxKG6P NWDBXZZsOTl2NkK5O|U>
Huh7 NYLsNol1SW62aY\pdoFtKEG|c3H5 NGDpcoszNjVizszN MlnLOEBl[Xm| NWnucFdmTE2VTx?= MkLETY5pcWKrdIOgeolz[Wxic4Dy[YFlKGmwIFTlcod2\SC4aYL1d{1qdm[nY4Tl[EBpfW2jbjDIeYg4KGOnbHzzJIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDv[kB3cXKjbDDlcpZmdG:yZTDwdo91\WmwIIfpeIhqdiCyZYLpcpVkdGWjcjDy[Ydqd25iYYSgNk42KHWP NVr4e2g{OTd|NkC2O|Y>
C6/36 MVLBcpRqfmm{YXygRZN{[Xl? NI\uT3QzNjVizszN NEHkcFQ1KGSjeYO= MmDtSG1UVw>? MXTJcohq[mm2czD2bZJidCC|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIF{cWGwIITp[4VzKG2xc4H1bZRwKEN4L{O2JINmdGy|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCxZjD2bZJidCCnbo\lcI9x\SCycn;0[YlvKHerdHjpckBx\XKrboXjcIVieiC{ZXfpc44h[XRiMj61JJVO NGjVe|gyPzN4ME[3Oi=>
U937 NVThNFFpTnWwY4Tpc44hSXO|YYm= MkjKNUDPxE1? NEHGVXcyKGh? NEjUdZFFVVOR NITiTmpT\WS3Y3XzJIJie2GuIGTOSoFteGijIILlcIVie2ViaX6gbJVu[W5iVUmzO{Bk\Wyucx?= MYmxO|Y5PDB7OR?=
U937 MlzySpVv[3Srb36gRZN{[Xl? M{nrSFEh|ryP M1;UZlEhcA>? M{Gw[mROW09? NFTScHRT\WS3Y3XzJGxRWy2rbnT1Z4VlKFSQRnHsdIhiKHKnbHXhd4UhcW5iaIXtZY4hXTl|NzDj[Yxtew>? MkHBNVc3QDRyOUm=
murine mast cell M{e0XGZ2dmO2aX;uJGF{e2G7 M364[|Eh|ryP NFTTboUzPCCq MYTEUXNQ M{\5RmlvcGmkaYTzJIFvfGmpZX6tbY5lfWOnZDDJUFYhe2WlcnX0bY9vKGmwIFnnSUBxemmvZXSgcY92e2VibXHzeEBk\WyuczDheEAyKHWP M3;hVVE4Pjh2MEm5
BV-173 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTQTWM2OD1yLkCwNFAxODFyOTFOwG0> Mnn4V2FPT0WU
K-562 NW[2UW5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfZNpFKSzVyPUCuNFAxODByMk[2JO69VQ>? NV7pPIdMW0GQR1XS
BL-70 M1rZR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwMECwNFAxQDJ{IN88US=> MXnTRW5ITVJ?
EM-2 NGDm[FBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFe3[JVKSzVyPUCuNFAxODBzMEig{txO M1X6UnNCVkeHUh?=
LAMA-84 NXP2NINKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTBwMECwNFA{OjFizszN NX3yXZhGW0GQR1XS
MEG-01 MlG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTBwMECwNFA6QCEQvF2= MknXV2FPT0WU
EoL-1-cell MoT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{m0d2lEPTB;MD6wNFAxOTNzIN88US=> MlriV2FPT0WU
CTV-1 M1fo[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1OxOmlEPTB;MD6wNFAxPDB2IN88US=> MYfTRW5ITVJ?
TE-15 NYPDWG01T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYezW3U2UUN3ME2wMlAxPTh7IN88US=> NIiwU2xUSU6JRWK=
NOS-1 M{jqXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTBwMEC2NVMh|ryP MnHWV2FPT0WU
D-336MG MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jmeWlEPTB;MD6wNFY{KM7:TR?= M1n5VHNCVkeHUh?=
LB1047-RCC MlLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3u0eWlEPTB;MD6wNFk5QSEQvF2= Mn2wV2FPT0WU
LB996-RCC MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYT2d29PUUN3ME2wMlAxQTlzIN88US=> NWnB[3dXW0GQR1XS
SW982 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mny0TWM2OD1yLkCxNVE2KM7:TR?= MVvTRW5ITVJ?
TK10 NEPne3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwMEGxO|Qh|ryP MXHTRW5ITVJ?
A704 NFPiXXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnn2TWM2OD1yLkCxOFkyKM7:TR?= MW\TRW5ITVJ?
TE-8 NUDoWnRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTBwMEG1O|Yh|ryP NHjMVWxUSU6JRWK=
DOHH-2 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnW1TWM2OD1yLkCxO|E6KM7:TR?= MVjTRW5ITVJ?
HOP-62 NGDw[WpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3mTIZKSzVyPUCuNFE5OzRizszN M2r3UXNCVkeHUh?=
TE-12 Mlq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH:3UlRKSzVyPUCuNFE5PjFizszN MWXTRW5ITVJ?
KGN NX;1dFhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHyfnNKSzVyPUCuNFE6PDJizszN MnXoV2FPT0WU
NCI-H1648 M1flSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWK2RmRCUUN3ME2wMlAzODFzIN88US=> M3\ySHNCVkeHUh?=
OS-RC-2 M3O2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrMfZdKSzVyPUCuNFIxOyEQvF2= NX\PNI5QW0GQR1XS
GB-1 NEPyZm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXFcWJKSzVyPUCuNFIyPTdizszN NGqwWJlUSU6JRWK=
RXF393 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TmW2lEPTB;MD6wNlM2PyEQvF2= NIDOc21USU6JRWK=
LC-2-ad M1nDXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwMEK1PFYh|ryP NIns[WdUSU6JRWK=
KS-1 NVTtVoh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPucI0zUUN3ME2wMlAzPzNizszN MmDQV2FPT0WU
ETK-1 NVvkWHFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVji[mUzUUN3ME2wMlAzQDN{IN88US=> NULpOnFvW0GQR1XS
SW954 M3jSPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwMEK5Nlch|ryP NH;lbmFUSU6JRWK=
Becker NFnBc2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7ud44zUUN3ME2wMlA{ODB|IN88US=> MlnKV2FPT0WU
MZ1-PC NWq1XoVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrrcJZKSzVyPUCuNFMyOTlizszN M4jMVnNCVkeHUh?=
ES6 M1zpc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnsc3dCUUN3ME2wMlA{OTl|IN88US=> NFu1XGFUSU6JRWK=
KURAMOCHI M3G3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XmOGlEPTB;MD6wN|Q5PyEQvF2= NXe5d|RUW0GQR1XS
CGTH-W-1 NUTubmJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XISGlEPTB;MD6wN|U1QCEQvF2= M2fvPHNCVkeHUh?=
VA-ES-BJ NWK1SHpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTBwMEO5NFIh|ryP NEe3e|JUSU6JRWK=
LXF-289 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTXTWM2OD1yLkCzPVU3KM7:TR?= M4fXW3NCVkeHUh?=
MPP-89 NVS1bJN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwMESwOFkh|ryP MlL4V2FPT0WU
SW872 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTYO2N{UUN3ME2wMlA1OTZzIN88US=> Ml\lV2FPT0WU
SNB75 MljtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwMES0N|Uh|ryP Ml7IV2FPT0WU
PSN1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\Od2lEPTB;MD6wOFQ4PCEQvF2= MV;TRW5ITVJ?
LB831-BLC Ml7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTWNFBZUUN3ME2wMlA1PjB7IN88US=> MVzTRW5ITVJ?
MFH-ino NIL1[m1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjaeFVKSzVyPUCuNFQ4OjRizszN M2HIXnNCVkeHUh?=
TGBC24TKB MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nobmlEPTB;MD6wOFc3OSEQvF2= M{\TcnNCVkeHUh?=
A388 NUTwOXBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XYTmlEPTB;MD6wOVA6PSEQvF2= M1vUW3NCVkeHUh?=
BB30-HNC NWfCcnFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zIfmlEPTB;MD6wOVQ{PyEQvF2= NFrid3ZUSU6JRWK=
GI-ME-N MmDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwME[xNVgh|ryP NHPxbZZUSU6JRWK=
TGBC1TKB MoCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3O3dGlEPTB;MD6wOlE3PCEQvF2= MYjTRW5ITVJ?
TE-10 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTBwME[zOVch|ryP MWfTRW5ITVJ?
A498 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHqXnlKSzVyPUCuNFczQDRizszN M17O[HNCVkeHUh?=
TE-11 NEKzOZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTBwMEe4OVgh|ryP M2\IfnNCVkeHUh?=
BB65-RCC Ml:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwMEiyNlch|ryP M3zw[HNCVkeHUh?=
C2BBe1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXPeIZKSzVyPUCuNFg{ODhizszN NETJfmRUSU6JRWK=
NCI-H747 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rMWGlEPTB;MD6wPFM3OiEQvF2= M134OnNCVkeHUh?=
IST-MES1 M1LQeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVe3UGo{UUN3ME2wMlA5PTV{IN88US=> MV;TRW5ITVJ?
KALS-1 NUDpdnlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnCOZc{UUN3ME2wMlA6PDlizszN NHHjNnFUSU6JRWK=
GCIY M{PqdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHw[pBKSzVyPUCuNFk3PTZizszN NH;nPJBUSU6JRWK=
RL95-2 NG\Jc5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHVTo9KSzVyPUCuNVA{QCEQvF2= MXHTRW5ITVJ?
TE-1 MlHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTBwMUC1OEDPxE1? M2PMSHNCVkeHUh?=
NCI-H1355 MoHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrvTWM2OD1yLkGxNFI5KM7:TR?= MmHNV2FPT0WU
SW962 NETzc21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmq3TWM2OD1yLkGxNlkzKM7:TR?= M3\QTnNCVkeHUh?=
KLE M1zJTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDvTWM2OD1yLkGxN|E4KM7:TR?= MmrzV2FPT0WU
MC116 NFLnSYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwMUG0NUDPxE1? M3fhXXNCVkeHUh?=
NMC-G1 M2PFSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfDTWM2OD1yLkGxOlA3KM7:TR?= M4q5eHNCVkeHUh?=
KU812 NG\kcHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlH6TWM2OD1yLkGxPFg{KM7:TR?= NWDlSmtPW0GQR1XS
COLO-829 NHi4OplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3QTWM2OD1yLkGyNlE{KM7:TR?= M3zPXXNCVkeHUh?=
NTERA-S-cl-D1 M1nYSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nPWGlEPTB;MD6xNlI5OyEQvF2= MlTFV2FPT0WU
IST-MEL1 NHLMWWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojNTWM2OD1yLkGzOFUh|ryP NGrrVIxUSU6JRWK=
MLMA NWixT|kzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwMUSwN|Ih|ryP NWjpXJZnW0GQR1XS
LS-123 M1:zUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGf5XFFKSzVyPUCuNVQxPjRizszN NH\DXJhUSU6JRWK=
LB2518-MEL MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3YVo9KSzVyPUCuNVQyPjJizszN MoPSV2FPT0WU
NB69 NHvqfmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnRdHdKSzVyPUCuNVQ1OzZizszN MlHsV2FPT0WU
8-MG-BA NGHJbGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXyfXI6UUN3ME2wMlE2PDV6IN88US=> NX[4[WZFW0GQR1XS
K5 NYn1NpJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwMU[0PFkh|ryP MoTqV2FPT0WU
KINGS-1 M{n6R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\4NmlEPTB;MD6xOlY3PiEQvF2= NGm4W4ZUSU6JRWK=
SF268 NWnTPVg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTWdlBKSzVyPUCuNVc1ODRizszN MVzTRW5ITVJ?
PF-382 M4mzZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\BTWM2OD1yLkG3Olc5KM7:TR?= NH7wdYpUSU6JRWK=
SH-4 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4frV2lEPTB;MD6xPFQyOyEQvF2= NG\uTHBUSU6JRWK=
NALM-6 Mnv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTBwMUmyPVUh|ryP NUjpN4ZKW0GQR1XS
CP66-MEL M4X1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LGdWlEPTB;MD6xPVU{OSEQvF2= MUnTRW5ITVJ?
697 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzVTWM2OD1yLkG5PVg4KM7:TR?= NEPXbHlUSU6JRWK=
CP67-MEL NXvVVZFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwMkC0PFgh|ryP M3f2eHNCVkeHUh?=
DSH1 Ml7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7KTWM2OD1yLkK0NFAyKM7:TR?= M3zjVnNCVkeHUh?=
HCE-4 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWP2eZZGUUN3ME2wMlI3PDN7IN88US=> NX\nd4tFW0GQR1XS
MZ2-MEL M3fq[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTVNWNzUUN3ME2wMlI5PTN5IN88US=> M1H3[3NCVkeHUh?=
BL-41 NX32dFcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDJdYI5UUN3ME2wMlI6OTJ|IN88US=> MlnVV2FPT0WU
HUTU-80 MlHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4K1XGlEPTB;MD6zNVQzKM7:TR?= MVfTRW5ITVJ?
LOXIMVI MnroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIW1dWtKSzVyPUCuN|E2ODNizszN NF3HcXdUSU6JRWK=
no-10 NFPkNIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTWb|JKSzVyPUCuN|E6OzFizszN NFXvUXhUSU6JRWK=
KARPAS-422 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;Hcph1UUN3ME2wMlM{QTl5IN88US=> M2\RRXNCVkeHUh?=
SW684 NEK1RWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13IPGlEPTB;MD6zOFk5KM7:TR?= NY\jWVZvW0GQR1XS
SF126 M3rLcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDoc2xGUUN3ME2wMlM2PDFizszN MnTpV2FPT0WU
D-263MG M{PZSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nibmlEPTB;MD6zOlIzPCEQvF2= NH\uOm1USU6JRWK=
OVCAR-4 M{fJTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkK4TWM2OD1yLkO3OFM{KM7:TR?= M1j4OHNCVkeHUh?=
BB49-HNC M{mxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3OxVWlEPTB;MD6zPFU6QSEQvF2= MULTRW5ITVJ?
ONS-76 M374eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXexOoo6UUN3ME2wMlQzQTVzIN88US=> NYq5TYNLW0GQR1XS
MZ7-mel NFLvUVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFexbW1KSzVyPUCuOFc6OTFizszN NWrKTIVIW0GQR1XS
RCC10RGB NXPV[HpGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzFVoJKSzVyPUCuOFkyOSEQvF2= M2jCZ3NCVkeHUh?=
BOKU MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXPTWM2OD1yLkS5NVM{KM7:TR?= M3nwOXNCVkeHUh?=
no-11 NFzWOWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXf2PWFxUUN3ME2wMlUxOjJ6IN88US=> MUPTRW5ITVJ?
IST-SL2 NYDTV41OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTOVIhKSzVyPUCuOVA{ODJizszN MVnTRW5ITVJ?
RKO M4rOR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnh[2xKSzVyPUCuOVI6PjZizszN NF7aW3FUSU6JRWK=
HT-144 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLFeoxiUUN3ME2wMlU{PjB7IN88US=> M2O4VXNCVkeHUh?=
NCI-H446 NEf2bpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHpSmJKSzVyPUCuOlI4PiEQvF2= M{DFR3NCVkeHUh?=
QIMR-WIL M120R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrtU4lKSzVyPUCuO|A3OjlizszN M4i0RXNCVkeHUh?=
MHH-PREB-1 NWrPXlJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWT3OXgxUUN3ME2wMlc1PDZ7IN88US=> NUnLb|Q6W0GQR1XS
EW-16 NXjifHdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DuZ2lEPTB;MD63OlE4QCEQvF2= NYHtS5lzW0GQR1XS
EW-24 NWCxfm1vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwN{ixOlUh|ryP MYLTRW5ITVJ?
LB373-MEL-D NULocGE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTBwOEK1NFgh|ryP NHrRN3RUSU6JRWK=
TE-9 NV2zOZN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXDTWM2OD1yLki3OVMzKM7:TR?= M1vEdHNCVkeHUh?=
A3-KAW MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzMTYpKSzVyPUCuPVg1PTJizszN M1K5RXNCVkeHUh?=
A101D Ml32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7UNJBKSzVyPUGuNFMxPDNizszN NID2SIxUSU6JRWK=
OCUB-M NEGwO2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnPeHZKSzVyPUGuNFQ1OTJizszN MVfTRW5ITVJ?
ES4 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLGTWM2OD1zLkC1NVQ2KM7:TR?= NHfCVYJUSU6JRWK=
TE-6 MlziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PCbWlEPTB;MT6yNVIzPiEQvF2= NUDFUWdKW0GQR1XS
D-502MG NGHabVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mki0TWM2OD1zLkKzN|c3KM7:TR?= NIfyT3dUSU6JRWK=
KNS-42 M2POWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTFwMkS0NVIh|ryP NYXD[WVNW0GQR1XS
SNU-C2B MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\VXWlEPTB;MT6zNFU5QSEQvF2= NXKy[2h7W0GQR1XS
NCI-H1838 MlLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7ETWM2OD1zLkOwO|M{KM7:TR?= MXvTRW5ITVJ?
NKM-1 NXS1OlgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXNdnJrUUN3ME2xMlMxQDV7IN88US=> NHW0XG9USU6JRWK=
GI-1 NVLRdIVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXUTWM2OD1zLkO2NlIh|ryP MoH5V2FPT0WU
NB5 NVzRV2ZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTFwM{m4Nlch|ryP M1u3SHNCVkeHUh?=
CAS-1 MkLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTFwNEC5PVIh|ryP MV\TRW5ITVJ?
HCE-T NEW3[HJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPrbopKSzVyPUGuOVY4OTRizszN NYqy[XQyW0GQR1XS
SBC-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LlfmlEPTB;MT61O|k5PCEQvF2= M1SyfHNCVkeHUh?=
JiyoyeP-2003 NFTJU4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIqyTWdKSzVyPUGuO|M1PjZizszN M1TjfHNCVkeHUh?=
TE-5 NGDXVVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TiSWlEPTB;MT63PVE{QSEQvF2= NV:2fHpxW0GQR1XS
CAN MnXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHVUphiUUN3ME2xMlgzOjV{IN88US=> M4fIT3NCVkeHUh?=
SK-UT-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfVO4VKSzVyPUKuNVY3QTNizszN NHHqOVhUSU6JRWK=
JVM-2 NFHBfIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2[0cWlEPTB;Mj6zOlI5PCEQvF2= MYTTRW5ITVJ?
LB771-HNC M4nMRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfNTm5HUUN3ME2yMlU4PTVzIN88US=> MX;TRW5ITVJ?
NCCIT NVzHRY12T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{SwWmlEPTB;Mj64OlYyPiEQvF2= MlGzV2FPT0WU
NCI-H2126 MnvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH73O2ZKSzVyPUKuPFc2PTJizszN MVfTRW5ITVJ?
Calu-6 NITHPWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nORmlEPTB;Mz6wOVc1OSEQvF2= M3;zNnNCVkeHUh?=
SK-LMS-1 MkjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1ywR2lEPTB;Mz6xNVg5PiEQvF2= MUHTRW5ITVJ?
ARH-77 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{f2[GlEPTB;Mz60OlkyPSEQvF2= M4XXbnNCVkeHUh?=
NB17 M2\QVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTNwNkO4OFch|ryP MWHTRW5ITVJ?
A253 NX3NW3pPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjiTWM2OD1|LkezNlQ3KM7:TR?= NX\HRpRlW0GQR1XS
OPM-2 M{fMUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfJbnlnUUN3ME20MlI4Pjh3IN88US=> MkDEV2FPT0WU
MV-4-11 MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFS2NnlKSzVyPUSuN|Y1PTRizszN MYDTRW5ITVJ?
SR MkiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PnTWlEPTB;ND60PVk2PCEQvF2= M1\rXXNCVkeHUh?=
KG-1 Ml\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nk[2lEPTB;ND62NFg1PSEQvF2= MoXYV2FPT0WU
OCI-AML2 Mkj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIftN3RKSzVyPUWuPFYyPTRizszN NVvONFF2W0GQR1XS
D-247MG M2j1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnITWM2OD14LkGyOVE6KM7:TR?= NGLJXGRUSU6JRWK=
DJM-1 NXHlWpE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvaN3lKSzVyPU[uOFg2PThizszN M2TDR3NCVkeHUh?=
RPMI-6666 M2n6R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HpU2lEPTB;Nz6yO|A3PyEQvF2= Mn\iV2FPT0WU
KARPAS-45 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPOR2NKSzVyPUeuOVE3PzFizszN MUHTRW5ITVJ?
LP-1 NFnqdZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDIXlN2UUN3ME23MlU1Pzh{IN88US=> MkLIV2FPT0WU
RS4-11 M3nBVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPofYRKSzVyPUeuOlU4QDdizszN NEXFeXNUSU6JRWK=
DU-4475 NV2xZXdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjRVZNKSzVyPUiuNlE3PTJizszN NEHLfppUSU6JRWK=
MONO-MAC-6 MmW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRThwMkewOlYh|ryP NGn1SYpUSU6JRWK=
NCI-SNU-16 NIfnUGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfqTWM2OD16LkW2NVI5KM7:TR?= M1\Gc3NCVkeHUh?=
SJSA-1 NGS5NoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TD[GlEPTB;OD63NlgxPSEQvF2= M4\3WXNCVkeHUh?=
MMAC-SF MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mly3TWM2OD16Lke5N|A4KM7:TR?= NYXMXnNMW0GQR1XS
SK-NEP-1 NH3Pc2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfYcmt1UUN3ME24Mlg6OTV3IN88US=> NX7OZmlZW0GQR1XS
J-RT3-T3-5 M1PVSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rnfWlEPTB;OD65OlUzQSEQvF2= Mo\FV2FPT0WU
SKM-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTlwMEG3N|Qh|ryP Mn3EV2FPT0WU
LB2241-RCC M3ToTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTlwMEKwNVIh|ryP MkLEV2FPT0WU
SIG-M5 MlW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vB[WlEPTB;OT6wNlQ6OyEQvF2= MVLTRW5ITVJ?
EVSA-T MonhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYX3SnNmUUN3ME25MlI4Pzl|IN88US=> MkXaV2FPT0WU
GT3TKB MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XWNmlEPTB;OT6zOVU1PiEQvF2= NESyTmRUSU6JRWK=
NB6 MkHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDPTWM2OD17LkmyNlU6KM7:TR?= NYfRN2pkW0GQR1XS
EHEB MlzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\6ZWlEPTB;MUCuNFY2PiEQvF2= NYrRd5dyW0GQR1XS
HEL MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vxVmlEPTB;MUCuOFc4PiEQvF2= NVLzUXVqW0GQR1XS
ALL-PO M3PkUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHL2UVFKSzVyPUGwMlc6OzhizszN NVO1O|JkW0GQR1XS
TGW M{LnNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTFzLkK4Nlgh|ryP NXrXTGRRW0GQR1XS
BC-3 MkntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HoSmlEPTB;MUKuNVE{QCEQvF2= NYrpSmNKW0GQR1XS
IA-LM Mo\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUewVYxSUUN3ME2xNk41PDR3IN88US=> M1PlPHNCVkeHUh?=
UACC-257 NF\6do1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;5TWM2OD1zMj65NVk5KM7:TR?= NVnPSppPW0GQR1XS
KP-N-YS NGezNFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fnbmlEPTB;MUKuPVI5OyEQvF2= MnzKV2FPT0WU
Raji NYHiZld[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TPXWlEPTB;MUOuO|Q6PyEQvF2= NYr5[5FXW0GQR1XS
SF539 M{HISWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfxTWM2OD1zMz64OVU4KM7:TR?= NUDJc|NRW0GQR1XS
DMS-153 M1jyd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPLc|g{UUN3ME2xOE4xODJ6IN88US=> MWnTRW5ITVJ?
L-540 MorsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzhTWM2OD1zNT6wOlczKM7:TR?= M4D6bHNCVkeHUh?=
MN-60 MnfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\T[HBKSzVyPUG1MlE6PzlizszN NXjuc2doW0GQR1XS
RPMI-8866 NIL0V5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fGc2lEPTB;MUeuOFQ2PCEQvF2= NWHLTJpLW0GQR1XS
NCI-H510A M3zROGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\TSo9KSzVyPUG5MlM6PzNizszN MmjFV2FPT0WU
NB13 MlP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3sRZZwUUN3ME2xPU41QDd5IN88US=> MkXsV2FPT0WU
HAL-01 NY\KUo9rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HRRWlEPTB;MUmuO|U1OyEQvF2= NGqzTGlUSU6JRWK=
NCI-H720 M{\qSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TPb2lEPTB;MkCuNlc{OyEQvF2= MlzHV2FPT0WU
REH MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTJyLk[zOVch|ryP MV3TRW5ITVJ?
KNS-81-FD NFznTItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfQ[VBKUUN3ME2yN{4yPDZizszN NVPu[2Q6W0GQR1XS
HC-1 NIXB[nhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3m4PGlEPTB;MkSuOVU2OSEQvF2= NH3kXWdUSU6JRWK=
NCI-H2141 M13hNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nMV2lEPTB;MkSuO|c2PCEQvF2= NG\IOmxUSU6JRWK=
MOLT-4 MlvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTJ4Lk[3OVMh|ryP NISzWnhUSU6JRWK=
OMC-1 M1P5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFL2TYlKSzVyPUK3MlE1OjJizszN MVLTRW5ITVJ?
LC-1F M3j4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NES1XZhKSzVyPUK3MlMzPDVizszN M4LU[HNCVkeHUh?=
NCI-H1304 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1raZmlEPTB;MkiuNVYzQCEQvF2= MYLTRW5ITVJ?
BC-1 M3jWd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfaR3BKSzVyPUK4MlY2OSEQvF2= NUm2eFFmW0GQR1XS
NCI-H64 M{TWdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTJ7Lk[yOVMh|ryP NHTJU|RUSU6JRWK=
MOLT-16 MmrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWD2NYs5UUN3ME2yPU43Ojl{IN88US=> NFzENGpUSU6JRWK=
U-87-MG MnHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTNyLke2OkDPxE1? MmXCV2FPT0WU
GAK MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTNzLkK2PFYh|ryP NGCxcFZUSU6JRWK=
ES8 MonQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLUVYdKUUN3ME2zNk4yOjV{IN88US=> MkHpV2FPT0WU
HCC1599 NH\LVplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLUcYJKSzVyPUOyMlM{OjVizszN NFvRTIVUSU6JRWK=
EB-3 M1u3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTN2LkOxNVch|ryP M4q0SXNCVkeHUh?=
HCC1187 M1zr[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3STWM2OD1|NT64NFUzKM7:TR?= NF3uO3BUSU6JRWK=
SK-PN-DW M2LYdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml[4TWM2OD1|Nj6xPVQ{KM7:TR?= MWnTRW5ITVJ?
JVM-3 MlfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTKUZgzUUN3ME2zO{4zOzN6IN88US=> M1HQPXNCVkeHUh?=
HCC2157 Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DuTWlEPTB;M{euPVk1PiEQvF2= NY[wTmd7W0GQR1XS
A4-Fuk MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnT4TWM2OD1|OD6xNFA6KM7:TR?= MmLYV2FPT0WU
COR-L279 Ml;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTRyLkK4OVEh|ryP M2\sWXNCVkeHUh?=
DEL NIrxU5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWe1fZlKUUN3ME20NU46ODh4IN88US=> MofjV2FPT0WU
NCI-H1395 NEfRSYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUG1OGtXUUN3ME20Nk4xOTZ|IN88US=> MV;TRW5ITVJ?
MHH-NB-11 NUHlS|NKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmr0TWM2OD12Mz6wPFE5KM7:TR?= NV3ZS4VbW0GQR1XS
NCI-H2107 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\yTWM2OD12Mz60PFQ3KM7:TR?= NED5TIxUSU6JRWK=
NEC8 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;STWM2OD12ND6zN|Yh|ryP MWLTRW5ITVJ?
COLO-684 M1TCdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLnUXNWUUN3ME20Ok4zOjV6IN88US=> M1G3SXNCVkeHUh?=
LS-411N M333cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvXTWM2OD12OD60O|Q5KM7:TR?= MmrKV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo試験 Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]
臨床試験 Dasatinib has entered in a phase II clinical trial in the treatment of hemangiopericytoma and gastrointestinal stromal tumor.
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Kinase autophosphorylation assays Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.

細胞アッセイ:

[1]

細胞株 Ba/F3 cell lines
濃度 ~32 nM
反応時間 72 hours
実験の流れ

Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.

動物実験:

[3]

動物モデル EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
製剤 DMSO
投薬量 30 mg/kg
投与方法 Administered via i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Dasatinib SDF
分子量 488.01
化学式

C22H26ClN7O2S

CAS No. 302962-49-8
保管 2年-20℃
6月-80℃in solvent
別名 BMS-354825
溶解度 (25°C) * In vitro DMSO 98 mg/mL (200.81 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 4% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide

カスタマーフィードバック (10)


Click to enlarge
Rating
Source Cell Res, 2011, 21, 1080-1087. Dasatinib purchased from Selleck
Method Microangiography
Cell Lines embryos
Concentrations 30 μM
Incubation Time
Results MEK1/2 may cooperate with VEGFR to regulate blood vessel lumen diameter. We examined this hypothesis by combining VEGFR inhibitor Sunitinib and MEK1/2 inhibitor U0126. Indeed, U0126 (10 µM) combined with Sunitinib (20 µM) resulted in a reduction of vessel lumen size (Figure F), whereas individually they did not. Combined treatment of another MAP kinase signaling pathway inhibitor Dasatinib (20 µM) with Sunitinib (20 µM) produced a similar phenotype as PP1, whereas each individual inhibitor did not result in any vessel shrinkage even at much higher concentrations ( Figure C).Since there are three major VEGF receptors, it is desirable to determine which receptor is involved in combinatory action with MEK1/2. To address this issue, additional highly selective VEGFR inhibitors PTK787 and ZM323881 were tested. Both of these inhibitors (PTK787 or ZM323881), when individually combined with Dasatinib or U0126, induced a reduction of vessel lumen size (Figure D, E, G, and H).

Click to enlarge
Rating
Source Clin Cancer Res, 2011, 17, 762-770. Dasatinib purchased from Selleck
Method Assessment of cell viability and apoptosis
Cell Lines B-CLL patient leukemic cells
Concentrations 2-10 μM
Incubation Time 48 h
Results The Dasatinib+Nutlin-3 combination promotes synergistic cytotoxicity in primary CLL cells as well as in p53 wild-type and p53 deleted/ mutated leukemic cell lines.

Click to enlarge
Rating
Source Clin Cancer Res, 2011, 17, 762-770. Dasatinib purchased from Selleck
Method Western blot
Cell Lines Leukemic cell lines
Concentrations 10 μM
Incubation Time 24 h
Results Dasatinib marginally affected both the basal levels of p53 and the accumulation of p53 induced by Nutlin-3 in the p53 wild -type cells (Fig. A).Interestingly, however, levels of both MDM2 and p21 proteins, 2 of the best characterized transcriptional targets of p53, weres significantly (P < 0.05) decreased in cells treated with Dasatinib+ Nutlin-3 with respect to cells treated with Nutlin-3 alone (Fig. B).

Click to enlarge
Rating
Source Clin Cancer Res, 2011, 17, 762-770. Dasatinib purchased from Selleck
Method Phospho-kinase array analysis
Cell Lines EHEB cell lines/BJAB cell lines
Concentrations 10 μM
Incubation Time 16 h
Results Although Nutlin-3 had no effects on these pathways, Dasatinib alone as well as Dasatinib+Nutlin-3 markedly inhibited the basal phosphorylation of ERK1/2, p38/MAPK, and Akt . Of interest, the combination of Dasatinib+Nutlin-3 selectively enhanced (P < 0.05) the inhibition of Akt phosphorylation with respect to Dasatinib alone, as validated by Western blot analysis.

Click to enlarge
Rating
Source Biochem Pharmacol , 2011, 82, 1457-1466. Dasatinib purchased from Selleck
Method MTT assay
Cell Lines MOLM-13 cells, HL-60 cells
Concentrations 1-15 μM
Incubation Time 24-72 h
Results Dasatinib and other TKI decreased the viability of the two myeloid cell lines in a dose- and time-dependent manner. Nevertheless, the anti-leukemic efficacy of Dasatinib and other TKI varied considerably in both cell lines.

Click to enlarge
Rating
Source Biochem Pharmacol , 2011, 82, 1457-1466. Dasatinib purchased from Selleck
Method Evaluation of differentiation
Cell Lines MOLM-13 cells, HL-60 cells
Concentrations 5 μM
Incubation Time
Results In a first series of experiments, we assessed four signs of morphological differentiation, May-Gruenwald-Giemsa staining of MOLM-13 cells demonstrated that dasatinib induced a dose-dependent decrease in cytoplasmic basophilia and in the nucleo-cytoplasmic ratio. Dasatinib also led to the appearance of dented nuclei and cytoplasmic granulation( Fig.A and B).In HL-60 cells,dasatinib(5 μM) once more exhibited the highest differentiation-inducing capacity. Thus dasatinib diminished basophilia of the cytoplasm concomitantly with the nucleo-cytoplasmic ratio, and induced the appearance of nuclear lobulation and cytoplasmic granules(Fig. G). Next, we determined the degree of CD11b expression, a marker indicating myeloid differentiation, in TKI-treated MOLM-13 dasatinib exhibited the most pronounced capacity to increase CD11b surface expression( Fig. C and D).To corroborate the TKI-driven differentiation, we quantified the enzymatic activity of alkaline phosphatase by means of the NBT-reduction assay after an incubation period of 6 days in MOLM-13 cells.,Once again, the NBT-reductive activity was highest in cells treated with dasatinib, which was as active as the positive control, ATRA( Fig. E and F)

Click to enlarge
Rating
Source Invest New Drugs , 2010, 30, 417-422. Dasatinib purchased from Selleck
Method Assessment of cell viability
Cell Lines leukemic cells
Concentrations 10 μM
Incubation Time 24/48 h
Results Dasatinib dose-dependently reduced cell viability in all leukemic cell lines, with variable efficacy irrespect ively of the p53 status. In particular, when used at 10 μM, Dasatinib induced a progressive decrease of the total number of viable cells ranging from approximately 30% (JVM-2 and MEC-2) to 50% (EHEB and BJAB) after 48 h of treat ment (Fig.a). In order to investigate whet her the decreased leukemic cell viability was mainly due to either cytotoxic or cytostatic activity, we have analyzed the effects of Dasatinib on apoptosis,As shown in Fig. b, exposure to Dasatinib induced a significant (p < 0.05) increase of apoptosis in all leukemic cell lines, as evaluated by Annexin-V/PI staining at 48 h of treatment.

Click to enlarge
Rating
Source Invest New Drugs , 2010, 30, 417-422. Dasatinib purchased from Selleck
Method phospho-kinase array analysis
Cell Lines EHEB (p53wt) cell lines, BJAB (p53mut) B cell lines
Concentrations
Incubation Time 24 h
Results As shown in Fig. a , the most evident effects of Dasatinib in both cell models were represented by a significant down-regulation of the phosphorylation levels of p38 MAPK, ERK1/2 and CREB. In addition, densitometric analysis of the phospho-kinase array demonstrated that Dasatinib also inhibited the phosphorylation levels of several STAT family members (STAT1, STAT2, STAT3, STAT5a/b and STAT6), the most evident effect in both p53 wild-type (EHEB) and p53 mutated (BJAB) cell lines being on STAT2, STAT3 and STAT6 (Fig. b)

Click to enlarge
Rating
Source Invest New Drugs , 2010, 30, 417-422. Dasatinib purchased from Selleck
Method Western blot
Cell Lines p53wild-type(EHEB, JVM-2) cell lines, p53mutated(MEC-2, BJAB) cell lines
Concentrations 10 μM
Incubation Time 24 h
Results "Upon exposure to Dasatinib, a decrease of phosphorylated proteins was confirmed by Western blot analys is in all cell lines investigated without significant differences between p53wild-type and p53mutated cell lines.

Click to enlarge
Rating
Source Dr. Thomas Kruwel of Fraunhofer-Institute for Toxicology and Experimental Medicine-Dasatinib (BMS-354825) purchased from Selleck. Dasatinib purchased from Selleck
Method Cell vability assays
Cell Lines A2C12, Beta D5, Gamma A3, Gamma D12, A549, CaCo2, HepG2 cell lines
Concentrations 0.001-1000 nM
Incubation Time 24/96 h
Results

文献中の引用 (61)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related Src 阻害剤

  • Dasatinib Monohydrate

    Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.

  • SU6656

    SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.

  • PX-478 2HCl

    PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.

  • Defactinib (VS-6063, PF-04554878)

    Defactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.

  • Saracatinib (AZD0530)

    Saracatinib(AZD0530)は、c-SrcのためのSrc阻害剤で、IC50 が2.7 nMです。

    Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

  • Bosutinib (SKI-606)

    Bosutinib(SKI-606)はそれぞれ1.2nMと1nMのIC50値による新しい二重Sarcoma/アベルソン(Src/Abl)チロシン・キナーゼ阻害剤です。

  • KX2-391

    KX2-391は、Srcのサブストレート結合部位を目標とする非常に選択的な非ATP Srcキナーゼ阻害剤で、Srcの高水準を表すガン細胞線で、非常に強い反増殖的な活性を示します。

  • PP1

    PP1は、Lck/Fynのための強力で選択的なSrc阻害剤で、IC50 が 5 nM/ 6 nMです。

  • PP2

    PP2は、Src キナーゼ阻害剤で、GST-Src活動を強力に禁止します。

最近チェックしたアイテム

Tags: Dasatinibを買う | Dasatinib供給者 | Dasatinibを購入する | Dasatinib費用 | Dasatinib生産者 | オーダーDasatinib | Dasatinib代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ